Scientis Pharma SA

Development of topical methima-zole to treat skin hyperpigmented lesions

Skin hyperpigmented lesions (mark of pregnancy, lenigos, post acne hyperpigmented scars etc.) are very frequent dermatologic problems. Such prob-lems have been treated since many years by creams containing hydroquinone as the active substance. Hydroquinone has been recently banned by FDA and European authorities since it has been identified as a toxic and carcinogenic compound. Methimazole is an FDA-approved oral medication used for the treatment of hyperthyroid-ism. We have shown, for the first time, that if methimazole is made into a cream (topical 5% methimazole) it removes the skin hyperpigmented lesions after 4-6 weeks of application in human.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

Scientis Pharma SA

Development of topical methima-zole to treat skin hyperpigmented lesions

Headquarter:
Genève

Foundation Date:
December 2010

Technology:

  • Biotech

Sectors:

  • Infection

Support received

  • Support venturekick